Format

Send to

Choose Destination
Am J Transplant. 2017 Jun;17(6):1574-1584. doi: 10.1111/ajt.14161. Epub 2017 Jan 25.

The Value of Protocol Biopsies to Identify Patients With De Novo Donor-Specific Antibody at High Risk for Allograft Loss.

Author information

1
William J. von Liebig Transplant Center, Mayo Clinic, Rochester, MN.
2
Joan and Sanford I. Weill Department of Medicine, Cornell Medical College, New York, NY.
3
Paul I. Terasaki Foundation, Los Angeles, CA.
4
Department of Internal Medicine, Division of Nephrology, University of Michigan, Ann Arbor, MI.
5
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.

Abstract

De novo donor-specific antibody (dnDSA) is associated with antibody-mediated rejection (AMR) and allograft loss, yet the allograft histology associated with dnDSA remains unclear. The aim of this study was to examine the allograft histology associated with dnDSA in patients with serial surveillance biopsies. We retrospectively studied adult conventional solitary kidney transplant recipients from October 2007 to May 2014. The definition of dnDSA was new donor-specific antibody (DSA) with mean fluorescence intensity (MFI) >1000. The incidence of dnDSA was 7.0% (54 of 771) over mean follow-up of 4.2 ± 1.9 years. Patients with dnDSA had reduced death-censored allograft survival (87.0% vs. 97.0% no dnDSA, p < 0.01). Moreover, 94% of patients received a biopsy after dnDSA (mean of three biopsies per patient). AMR was present in 25.0% and 52.9% of patients at dnDSA detection and at 1 year, respectively. Patients with both class I and II dnDSA had the highest rate of allograft loss. The higher the sum MFI at dnDSA detection, the higher the incidence of AMR. In conclusion, patients with dnDSA without AMR at time of detection may benefit from a follow-up biopsy within 1 year because AMR can be missed initially. In addition, the dnDSA class and sum MFI at baseline appear to be prognostic. The higher the sum MFI of dnDSA at baseline, the higher the incidence of AMR.

KEYWORDS:

alloantibody; biopsy; clinical research/practice; immunosuppressive regimens; induction; kidney (allograft) function/dysfunction; kidney transplantation/nephrology; rejection: antibody-mediated (ABMR)

PMID:
27977905
PMCID:
PMC5445019
DOI:
10.1111/ajt.14161
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center